Risk of adverse COVID-19 outcomes for people living with HIV: a rapid review and meta-analysis

Running head: HIV & COVID-19 outcomes: review & meta-analysis

Authors: Maya M. MELLOR¹, Anne C. BAST¹, Nicholas R. JONES², Nia W. ROBERTS³, José M. ORDÓÑEZ-MENA²,⁶, Alastair J.M. REITH¹, Christopher C. BUTLER², Philippa C. MATTHEWS⁴,⁵, Jienchi DORWARD²,⁷

Affiliations:
1: Medical Sciences Division, University of Oxford, Oxford, UK
2: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
3: Outreach Librarian Knowledge Centre, Bodleian Health Care Libraries, Oxford, UK
4: Nuffield Department of Medicine, University of Oxford, Oxford, UK
5: Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
6: NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
7: Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa

Corresponding author: Jienchi Dorward, Nuffield Department of Primary Care Health Sciences, Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Rd, Oxford OX2 6GG, United Kingdom, jienchi.dorward@phc.ox.ac.uk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Requests for reprints: Jienchi Dorward, Radcliffe Primary Care Building, Nuffield Department of Primary Care Health Sciences, Radcliffe Observatory Quarter, Woodstock Rd, Oxford OX2 6GG, United Kingdom, jienchi.dorward@phc.ox.ac.uk

Funding: This work was supported by funding from the Wellcome Trust (216421/Z/19/Z).

Word count: 2498/2500
Abstract: (250/250 words)

Objective: To assess whether people living with HIV (PLWH) are at increased risk of COVID-19 mortality or adverse outcomes, and whether antiretroviral therapy (ART) influences this risk.

Design: Rapid review with meta-analysis and narrative synthesis.

Methods: We searched databases including Embase, Medline, medRxiv, and Google Scholar up to 26th August 2020 for studies describing COVID-19 outcomes in PLWH and conducted a meta-analysis of higher quality studies.

Results: We identified 1,908 studies and included 19 in the review. In a meta-analysis of five studies, PLWH had a higher risk of COVID-19 mortality (hazard ratio (HR) 1.93, 95% Confidence Interval (CI): 1.59-2.34) compared to people without HIV. Risk of death remained elevated for PLWH in a subgroup analysis of hospitalised cohorts (HR 1.54, 95% CI: 1.05-2.24) and studies of PLWH across all settings (HR 2.08, 95%CI: 1.69-2.56). Eight other studies assessed the association between HIV and COVID-19 outcomes, but provided inconclusive, lower-quality evidence due to potential confounding and selection bias.

There were insufficient data on the effect of CD4+ T cell count and HIV viral load on COVID-19 outcomes. Eleven studies reported COVID-19 outcomes by ART-regimen. In the two largest studies, tenofovir-disoproxil-fumarate (TDF)-based regimens were associated with a lower risk of adverse COVID-19 outcomes, although these analyses are susceptible to confounding by comorbidities.

Conclusion: Evidence is emerging that suggests a moderately increased risk of COVID-19 mortality amongst PLWH. Further investigation into the relationship between COVID-19 outcomes and CD4+ T cell count, HIV viral load, ART and the use of TDF is warranted.

Keywords: HIV; AIDS; COVID-19; SARS-CoV-2; Antiretroviral therapy
Introduction:

By September 2020, over 30 million people worldwide had been diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1]. Although SARS-CoV-2 infection may be asymptomatic or cause only mild symptoms, a proportion of people develop severe coronavirus disease 2019 (COVID-19), leading to hospitalisation, acute respiratory distress syndrome or death. Established risk factors for severe COVID-19 among the general population include older age, chronic kidney disease and obesity [2].

People living with HIV (PLWH), who constitute approximately 0.5% of the global population [3], may have an increased risk of adverse outcomes from COVID-19 as a result of HIV-associated immune dysfunction [4]. There may also be a higher prevalence of comorbidities amongst PLWH that predispose to unfavourable COVID-19 outcomes [5]. Some antiretroviral agents are under consideration as potential treatments for COVID-19 [6], but the influence of antiretroviral therapy (ART) on COVID-19 outcomes is not known. In this rapid review, we aim to evaluate the evidence regarding the risk of adverse COVID-19 outcomes in PLWH, and the extent to which this risk is modified by other factors including ART.

Methods:

We used rapid review methods to identify studies between 1st January and 26th August 2020 that described COVID-19 outcomes in PLWH and compared outcomes with HIV-negative people or the general population, or that compared outcomes by risk factors amongst PLWH. We searched Embase, Medline, medRxiv, LitCovid, Trip, Google and Google Scholar without language restrictions. Search terms are available in Table S1. One author with extensive literature search expertise performed the initial screen to exclude duplicates and studies not related to HIV. For remaining articles, one author performed title and abstract
screening, with subsequent full text review by two authors using a standardised data extraction form. Disagreements were resolved by a third author. We included pre-prints in order to capture emerging evidence. Studies with ≤15 participants were excluded as they were unlikely to be powered to detect meaningful associations. We critically appraised the quality of studies using checklists for Case Series and for Cohort Studies from the Joanna Briggs Institute [7].

Cohort studies reporting COVID-19-related death in people with and without HIV that adjusted for age, sex and comorbidities were included in a meta-analysis. Cohort-specific relative risks (RRs) and hazard ratios (HRs) were combined with random effects model to account for variability of the true effect between studies. HRs and RRs numerically approximate each other with shorter follow-up, rarer endpoints, and risks closer to 1 [8]. Subgroup analyses were conducted by study setting and method of confounder adjustment. Meta-analysis was performed in R (version 3.6.0) using the meta package [9].

**Results:**

**Summary of included studies**

We identified 1,908 records and included 19 studies in our final qualitative analysis (Figure 1). Seventeen studies [10–26] were peer-reviewed and two were preprints [27,28]. Quality appraisal is included in Tables 1, S2 and S3.

We identified five cohort studies (two prospective, three retrospective) comparing COVID-19 related mortality between PLWH and HIV-negative people, which we pooled in a meta-analysis [10,16,18,27,28]. Four of these reported all-cause mortality among people diagnosed with COVID-19 [10,16,18,28] and one reported mortality due to COVID-19 as recorded on death certificates [27]. Of the remaining fourteen studies, seven made multiple comparisons between PLWH with COVID-19 and HIV-negative cohorts, and/or the general population,
and/or PLWH without COVID-19, [11,12,14,15,23,25,26], two studies compared only to a
HIV-negative cohort [13,19], two studies compared only cohorts of PLWH with and without
COVID-19 [17,22] and three studies compared only the characteristics of PLWH with
different COVID-19 disease severity [20,21,24].

There were ten studies that included a total of >1,000 individuals, but amongst these the
median number of PLWH with COVID-19 co-infection was only 55 (interquartile range 35-
115). Seventeen of the studies were performed in high-income countries and most included a
majority of patients on ART with well-controlled HIV (Table 1).

Quality of evidence and risk of bias assessment

There were common limitations among the included studies. Most were retrospective
analyses of routinely-collected clinical data, meaning identification of COVID-19 cases was
not systematic and depended on the local approach to screening and diagnosis. This has
varied over time and between settings, and may also differ between PLWH and the general
population. Only five studies directly compared COVID-19 outcomes amongst PLWH and
HIV-negative people in the same cohort, and accounted adequately for potential confounding
by co-morbidities associated with adverse COVID-19 outcomes. Other studies used
inadequately matched HIV-negative controls, or the general population, which is susceptible
to bias as the exposed and control groups were selected differently. Across all studies, the
numbers of PLWH and COVID-19 infection were relatively low.

Adjusted analyses of HIV and risk of death in COVID-19:

In a meta-analysis of five cohort studies which accounted for confounding, the risk of death
from COVID-19 for PLWH was almost double that of HIV-negative people (HR=1.93, 95%
confidence interval [CI] 1.59-2.34) (Figure 1) [10,16,18,27,28]. Three of these studies used
large routine databases to identify PLWH across community and hospital settings, in South
Africa [18], the United Kingdom (UK) [27] and United States of America (USA) [10], and two studies were limited to hospitalised PLWH and COVID-19 in the UK [28] and USA [16]. In a subgroup analysis there was no significant difference between study settings (p=0.17), although a weaker HR was seen in hospitalised patients (Figure S1). Among the three studies which used multivariable adjustment to account for confounding [18, 27, 28], the crude risk of COVID-19 death was similar between people with and without HIV, but after adjustment for age, the adjusted risk amongst PLWH was higher. Subsequent adjustment for comorbidities did not drastically alter HRs (Table 1). In sub-group analysis by method of accounting for confounders, a weaker HR was seen in the smaller two studies which used propensity score matching (Figure S2) [10, 16].

**Adjusted analyses of risk of hospitalisation and morbidity in PLWH:**

Three of the five cohort studies conducted analyses of the association between HIV status and the risk of other COVID-19 outcomes [10, 16, 28]. Amongst 47,539 individuals hospitalised with COVID-19 in the UK, the odds of critical care admission was higher among the 115 PLWH (odds ratio (OR) 2.60, 95% CI 1.74-3.87), but this was attenuated after adjustment for demographics and co-morbidities (aOR 1.13, 95% CI 0.72-1.75) [28]. In the analysis of 50,167 people with COVID-19 in the USA, 404 PLWH (n=404) were at increased risk of hospitalisation compared to 1:1 propensity score matched HIV-negative controls (RR 1.70, 95% CI: 1.21-2.38) [10]. Lastly, among 2,638 people hospitalised with COVID-19 in the USA, there were 6 (28.6%) intensive care unit admissions among 21 PLWH, compared to 7 (16.7%) amongst a propensity score matched cohort of 42 HIV negative people (p = 0.271) [16].

**Unadjusted analyses of COVID-19 related outcomes in PLWH:**
Eight studies provided lower-quality evidence regarding COVID-19 outcomes in PLWH as they did not compare HIV-positive and negative people in the same cohort, or did not adequately account for confounders. The largest of these was a Spanish multi-centre study of 77,590 PLWH, of whom 236 were diagnosed with COVID-19 and 20 died. In keeping with our meta-analysis result, age- and sex-standardised mortality from COVID-19 were found to be higher in PLWH (3.7 per 10,000) compared to the general population (2.1 per 10,000) [11]. The other seven studies [12–15,19,25,26] were limited due to being at single sites, having small sample sizes (median 64, range n=31-161 PLWH diagnosed with COVID-19) and not accounting for potential confounding. These studies report conflicting results with one suggesting a higher rate of hospitalisation and mortality among PLWH compared to the general COVID-19-positive population [12], two studies suggesting lower COVID-19 mortality in PLWH [14,25] and four studies reporting no significant difference in the risk of adverse outcomes from COVID-19 between PLWH and HIV-negative cohorts [13,19] or the general population [15,26].

Risk of death and hospitalisation in relation to CD4+ T cell count and HIV viral load:

Several of the large cohort studies did not include data on CD4+ T cell count or HIV viral loads [10,27,28]. In the South African study, lower CD4+ T cell counts (measured during the COVID-19 episode) were associated with mortality, but this could be a result of, rather than causing, severe disease (Table 2). There was no difference in outcomes by HIV viral load, although viral load data was incomplete and numbers with unsuppressed viral loads were small [18]. A London HIV clinic found that 18 PLWH who were hospitalised with COVID-19 had a lower median CD4+ T cell count (395 vs 573 cells/µL, p=0.03) compared to their 2,699 PLWH outpatients (Table 2) [17]. A further nine studies (median n= 54 PLWH and
COVID-19, range n=35-93) found no significant association between CD4+ T cell count or HIV viral load and COVID-19 outcomes [13,14,16,20–24,26].

**Impact of ART regimen on COVID-19 outcomes:**

No studies compared COVID-19 outcomes between PLWH receiving and not receiving ART. We identified eleven studies assessing the relationship between specific ART regimens and COVID-19 outcomes in PLWH. In South Africa, COVID-19 related mortality was lower in patients on TDF-based regimens versus abacavir/zidovudine-based regimens, which are used for patients with co-morbidities or requiring second line treatment (aHR: 0.42; 95% CI: 0.22-0.78) [18]. While this analysis was adjusted for certain co-morbidities, the observed association may be confounded due to patients receiving TDF having less complex healthcare needs. In the Spanish multi-centre study, PLWH receiving TDF and emtricitabine (FTC) had the lowest risk for COVID-19 diagnosis (16.9 per 10,000) and hospitalisation (10.5 per 10,000) compared to all other ART regimens investigated, but without adjusting for co-morbidities [11]. A US hospital study found that PLWH and COVID-19 who survived were more likely to have been treated with NRTIs that those PLWH who died (99% vs 89%, p=0.04) in univariate analysis [13]. Seven smaller studies (n=18-93 PLWH with COVID-19) reported no significant association between ART-regimen and COVID-19 severity amongst PLWH [14,15,17,20–24].

**Other factors influencing COVID-19 outcomes among PLWH:**

Thirteen studies assessed the influence of comorbidities and demographics on the outcomes of COVID-19 amongst PLWH [13,14,16–18,20–24,26–28]. In the UK-based cohort study of hospitalised patients, among 115 PLWH with COVID-19, the 26 who died were more likely to have obesity and diabetes [28]. Bhaskaran et al and Childs et al report evidence of a higher risk of COVID-19 death and hospitalisation respectively amongst PLWH of black ethnicity...
(Bhaskaran et al mortality aHR=3.80; 95% CI: 2.15-6.74, p for interaction=0.045; Childs et al hospitalisation crude OR: 12.22, 95% CI: 1.62-92.00) [17,27]. Other smaller analyses suggested that amongst PLWH, factors such as older age [23], metabolic disorders [23], obesity [14], African ethnicity [23] and organ transplantation [13] were associated with COVID-19 infection or severity.

**Discussion:**

**Summary**

Emerging evidence suggests an increased risk of COVID-19 related death in PLWH. There was insufficient data to determine whether HIV viral load, CD4+ T cell counts or ART use are associated with COVID-19 related death. We found some evidence that among PLWH receiving ART, TDF use may be associated with lower frequency of SARS-CoV-2 infection and milder courses of COVID-19, although this was not consistent between studies and was susceptible to confounding. Risk factors for severe COVID-19 among PLWH include older age, obesity and black ethnicity, and appear similar to the general population.

**Risk of COVID-19 related mortality among PLWH**

In our review, the two population-based studies from South Africa and the UK both suggested almost double the risk of COVID-19 related death amongst PLWH, despite having very different demographic profiles [18,27]. In contrast, studies restricted to cohorts of PLWH diagnosed with COVID-19 [10], and hospitalised patients with COVID-19 [16,28] found a weaker or null effect. These studies are more at risk of selection bias, as PLWH with milder symptoms may be more likely to test for SARS-CoV-2 or be hospitalised by clinicians (due to a higher perceived risk), compared to people without HIV who may only be tested or hospitalised once more severely unwell. This would lead to the cohort of PLWH being less unwell at baseline compared to the HIV negative cohort, leading to underestimation of any
association between HIV status and COVID-19 related mortality. Furthermore, studies restricted to hospitalised patients cannot account for the effect of HIV (or any other potential risk factor) on SARS-CoV-2 infection and COVID-19 severity which result in hospitalisation, and therefore may underestimate the effect of risk factors on COVID-19 death, compared to studies in the general population [29].

**Influence of ART**

We found no evidence to determine whether ART reduces COVID-19 severity through immune reconstitution, as most studies included PLWH on ART. Regarding specific antiretrovirals, the potential therapeutic value of TDF for COVID-19 is supported by results from molecular docking studies [30]. However, TDF is relatively contra-indicated in renal impairment [31], meaning patients receiving TDF-based ART are likely to have less comorbidities, which may explain the observed better COVID-19 outcomes. Randomised trials of TDF prophylaxis for SARS-CoV-2 are underway [32].

**Comparisons with existing literature**

PLWH are known to be at higher risk of respiratory bacterial infections, but the evidence regarding acute viral infections is less clear [33]. A review from the H1N1 influenza pandemic in 2009/2010 found some evidence of a higher risk of adverse H1N1 outcomes amongst PLWH who were severely immunocompromised [34]. However, the quality of the evidence was weak with a lack of rigorously-designed prospective cohort studies, reflecting the challenges of in-pandemic research [34].

As of August 26th 2020, we identified seven systematic reviews on COVID-19 in PLWH [35–41]. All these reviews lacked the more robust evidence from recent large cohort studies [18,27,28]. Moreover, one review included articles assessing non-HIV related immunodeficiency [38] and four did not address the influence of ART [35,39–41].
Limitations

Our meta-analysis of five studies is potentially limited by the small numbers of PLWH with COVID-19 who died. This presented challenges when accounting for confounding; studies that used multivariable analyses to adjust for confounding were susceptible to over-fitting of models and potential over-adjustment by factors which could be on the causal pathway between HIV and death (e.g. malignancy or tuberculosis). Studies that used matching were potentially under-powered, which may explain why they tended to report no independent association between HIV and COVID-19 death. In our narrative synthesis, the majority of the studies were small case series or cohort studies that did not adequately account for confounders such as age. Most were performed in high-income countries, and the majority of participants had well-controlled HIV on ART. This may limit the applicability to populations of PLWH in other settings. Only 68% of adults and 53% of children living with HIV globally are receiving ART [42], highlighting a crucial need to examine the risk of COVID-19 complications in these populations.

Conclusion:

We present evidence which suggests a moderately increased risk of COVID-19 death among PLWH. TDF-based ART may be associated with lower risk of COVID-19 diagnosis and adverse outcomes, although this finding is susceptible to confounding. Measures to mitigate COVID-19 risk among PLWH should be included in the global pandemic response, while further research into the role of ART, immunosuppression and viral suppression is needed to quantify and address risks for PLWH in diverse settings.
Acknowledgements:

MM, NJ and JD conceived the study. NR performed the literature search. MM and AB contributed equally to the screening and qualitative analysis, with support from NJ and JD. JOM performed the meta-analysis. MM and AB wrote the first draft of the manuscript. MM, AB, NR, JOM, AR, CB, PM, NJ and JD critically reviewed and edited the manuscript and consented to publication.

Conflicts of Interest and Source of Funding:

There are no conflicts of interest to declare. NJ and JD are funded by the Wellcome Trust PhD Programme for Primary Care Clinicians (216421/Z/19/Z).
References


9  Schwarzer G. **Package “meta” Title General Package for Meta-Analysis. R News**
Published Online First: 2007. doi:10.1007/978-3-319-21416

10  Hadi YB, Naqvi SFZ, Kupec JT, Sarwari AR. **Characteristics and outcomes of COVID-19 in patients with HIV: a multi-center research network study. AIDS**
Published Online First: 2020. doi:10.1097/QAD.0000000000002666


Immune Defic Syndr Published Online First: 2020.
doi:10.1097/QAI.0000000000002423


doi:10.1093/cid/ciaa1198


doi:10.1097/qad.0000000000002651

Clinical characteristics, risk factors, and incidence of symptomatic COVID-19 in adults living with HIV. *Aids* 2020; Publish Ah. doi:10.1097/qad.0000000000002643


39 Mirzaei H, McFarland W, Karamouzian M, Sharifi H. COVID-19 Among People


42 World Health Organisation. *HIV/AIDS Fact Sheet*. 
### Table 1: Details of all included studies with summary of mortality findings and quality appraisal

<table>
<thead>
<tr>
<th>Study details</th>
<th>Location</th>
<th>Study type and study population</th>
<th>Characteristics of PLWH</th>
<th>Mortality</th>
<th>Quality appraisal*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>STUDIES INCLUDING ALL COVID-19 PATIENTS (HOSPITALISED AND IN THE COMMUNITY)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boulle et al, (2020) [18]</td>
<td>Multi centre: Western Cape, South Africa</td>
<td>Prospective cohort study of 540,552 PLWH (3978 confirmed COVID-19) &amp; 2,920,380 HIV-negative adults (18,330 confirmed COVID-19)</td>
<td>34% male, median age 20-39 years. No data on proportions by ethnicity, ART, or any co-morbidity. 7.6% with VL. 7000 copies/ml or CD &lt; 200 cells/µL, 34.7% with VL unknown in past 15 months.</td>
<td>115 (2.1/10,000) COVID-19 deaths in PLWH vs 510 (1.7/10,000) in adults without HIV. Adjusted for age &amp; sex, aHR: 1.97; 95% CI: 1.59-2.45. Adjusted for age, sex &amp; co-morbidities: aHR: 2.14; 95% CI: 1.70-2.70 1.</td>
<td>JBI C = 11. Risk of confounding by socio-economic status &amp; BMI.</td>
</tr>
<tr>
<td>Bhaskaran et al, (2020) [27]</td>
<td>Multi centre, United Kingdom</td>
<td>Retrospective population-based cohort analysis of primary care data of 27,480 PLWH and 17,255,425 adults without HIV. Numbers diagnosed with COVID-19 not presented.</td>
<td>65% male, median age 40-55 years, 46.2% White, 5.1% Mixed, 4.3% South Asian, 26% Black, 2.3% Other. No data on proportions with any co-morbidity, or by ART, CD4+ count, viral suppression</td>
<td>25 (9.1/10,000) COVID-19 deaths in PLWH vs 14,875 (8.6/10,000) in adults without HIV. Adjusted for age &amp; sex, aHR: 2.90, 95% CI: 1.96-4.30. Adjusted for age, sex &amp; co-morbidities, aHR 2.30; 95% CI: 1.55-3.41 2.</td>
<td>JBI C = 11. Small number of outcomes amongst PLWH therefore possible overfitting of model.</td>
</tr>
<tr>
<td>Hadi et al, [10], 2020</td>
<td>Multi centre, United States</td>
<td>Retrospective cohort study amongst people with SARS-CoV-2 infection comparing 404 PLWH with 49,763 adults without HIV. (including matched cohort of 404 adults3)</td>
<td>71% male, mean age 48.1, 50% Black or African American, 34% White, 13% Latinx, 3% Asian. No data on proportions with any co-morbidity. 70% on ART, no data on CD4 count or VL.</td>
<td>20 (4.95%) COVID-19 deaths in PLWH vs 1585 (3.19%, risk ratio [RR] 1.55, 95% CI: 1.01 – 2.39) in unmatched cohort, and 15 (3.71%, RR 1.33, 95% CI: 0.69 – 2.57) in matched cohort.</td>
<td>JBI C = 10. Unclear how COVID-19 diagnosed. 1:1 matching may result in underpowered analysis.</td>
</tr>
<tr>
<td>del Amo et al, (2020)</td>
<td>Multi centre, 60 Spanish HIV clinics</td>
<td>Cohort study of 236 PLWH receiving ART with COVID-19, recruited from 77,590 patients of HIV clinics</td>
<td>75% male, median age 50-59 years. 100% receiving ART. No data on ethnicity, CD4 count, viral load or other co-morbidities. 64% hospitalised, 6% in ICU.</td>
<td>20 (8%) PLWH died, giving age and sex standardised risk of death of 3.7/10,000 vs 2.1/10,000 in general Spanish population</td>
<td>JBI C = 7. Comparison group from a different population. Confounding factors not accounted for.</td>
</tr>
<tr>
<td>Authors</td>
<td>Study Type</td>
<td>Study Design</td>
<td>Population</td>
<td>Characteristics</td>
<td>Mortality</td>
</tr>
<tr>
<td>--------------------</td>
<td>----------------</td>
<td>--------------</td>
<td>-------------------------------------------------</td>
<td>-----------------------------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Miyashita et al</td>
<td>Cohort study</td>
<td>Multi-centre</td>
<td>People with SARS-CoV-2 infection vs people without HIV</td>
<td>78% male, median age 51-65 years. No data on ethnicity, ART, CD4, VL, or proportion with any comorbidity</td>
<td>23 (14%) PLWH died vs 1235 (14%) without HIV accounted for. Insufficient follow up time for some patients.</td>
</tr>
<tr>
<td>Ho et al [20], 2020</td>
<td>Case series</td>
<td>Multi-centre</td>
<td>PLWH with positive SARS-CoV-2 test</td>
<td>72% male, median age 58 years, 40.9% Black, 31.2% Hispanic/Latinx, 96% on ART, 84% VL &lt;50 copies/ml, median CD4 554 cells/µL.</td>
<td>19 (20.4%) PLWH died, no mortality comparison given</td>
</tr>
<tr>
<td>Di Biagio et al</td>
<td>Case series</td>
<td>Multi-centre</td>
<td>PLWH with SARS-CoV-2 infection</td>
<td>72% male, median age 50-55, 86% Caucasian, 100% on ART, 88% VL &lt; 50 copies/ml, median CD4 580-600 cells/µL.</td>
<td>7 (10.8% of those with known outcomes) PLWH died, no mortality comparison given</td>
</tr>
<tr>
<td>Maggio et al</td>
<td>Cohort study</td>
<td>Single-centre</td>
<td>PLWH with suspected/confirmed COVID-19 vs PLWH with no COVID-19</td>
<td>80% male, median age 54 (IQR: 49-58), 100% receiving ART, 98% VL &lt;50 copies/ml, median last CD4 count 904 cells/µL, 51% with any co-morbidity.</td>
<td>4 (7.2%) PLWH died, no mortality comparison given</td>
</tr>
<tr>
<td>Etienne et al</td>
<td>Case series</td>
<td>Single centre</td>
<td>PLWH with symptoms or were hospitalised with COVID-19</td>
<td>61.1% male, median age 54, 100% on ART, 96.2% VL &lt; 40 copies/mL, median CD4 count 583 cells/mm³, 44.6% Sub Saharan African origin</td>
<td>1 (1.9%) PLWH died, no mortality comparison given</td>
</tr>
<tr>
<td>Inciarte et al</td>
<td>Cohort study</td>
<td>Single centre</td>
<td>PLWH with confirmed or suspected COVID-19</td>
<td>85% male, median age 44, median last CD4 cells/mm³ 618 (IQR: 449-834), 96% on ART</td>
<td>2 (4%) PLWH died, no mortality comparison given</td>
</tr>
<tr>
<td>Gervasoni et al</td>
<td>Case series</td>
<td>Single centre</td>
<td>PLWH with suspected/confirmed COVID-19</td>
<td>74% male, median age 52 years, no ethnicity data. 100% receiving ART, median CD4 count 636 cells/µL, 93.6% with undetectable VL, 64% with ≥1 comorbidity.</td>
<td>2 PLWH died (4.2% of cohort, 15.4% of those hospitalised with COVID-19) vs 17% died among 502 HIV-negative patients admitted with COVID-19 at same hospital</td>
</tr>
<tr>
<td>Study</td>
<td>Study Design</td>
<td>Setting</td>
<td>Population Characteristics</td>
<td>Outcome</td>
<td>Comparison Group</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------</td>
<td>--------------------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Huang et al [26], 2020</td>
<td>Cohort study of 600 PLWH of whom 35 were diagnosed with COVID-19</td>
<td>Wuhan City, China</td>
<td>90% male, median age 37 years, no data on ethnicity. 92% on ART, median CD4 count 200-499 cells/µL, 66% VL &lt; 20 copies/mL.</td>
<td>2 (5.7%) PLWH with COVID-19 died vs 3869/50333 (7.69%) of general population of Wuhan with COVID-19</td>
<td>JBI C = 5. Comparison group from a different population. Follow-up not clear. Confounding not accounted for.</td>
</tr>
<tr>
<td>Härter et al [12], 2020</td>
<td>Case series of 33 PLWH with confirmed COVID-19</td>
<td>12 German HIV centres</td>
<td>91% male, median age 48 years, no ethnicity data. 100% receiving ART, overall median CD4 count 670 cells/µL, 94% virally suppressed, 60% with ≥1 comorbidity</td>
<td>3 PLWH died (9.1%) vs 3.7% mortality in general COVID19 positive population in Germany</td>
<td>JBI CS = 7. Comparison group from a different population and confounding not accounted for. Not all patients with an outcome.</td>
</tr>
<tr>
<td>Geretti et al [28], 2020</td>
<td>Prospective cohort study of people hospitalised with suspected/confirmed COVID-19 vs 47,424 HIV-negative adults</td>
<td>Multi centre: 207 UK hospitals</td>
<td>66% male, median age 49-61 years. White (41.5%), Black (45.3%), Asian (0.9%), Other (12.3%), 74% ≥ 1 comorbidity. No data on proportions by ART, CD4 or VL.</td>
<td>26 PLWH died (23%) vs 13,955 (29%) in adults without HIV. Adjusted for age &amp; sex, aHR: 1.39; 95% CI: 0.93-2.08. Adjusted for age, sex and co-morbidities, aHR: 1.63; 95% CI: 1.07-2.48, p=0.024.</td>
<td>JBI C = 9. 10% with missing outcome data.</td>
</tr>
<tr>
<td>Sigel et al [13], 2020</td>
<td>Cohort study of 88 PLWH hospitalised with laboratory confirmed COVID-19 compared to matched cohort of 405 hospitalised HIV-negative adults</td>
<td>New York, US</td>
<td>78% male, median age 45-67 years. Ethnicity: White (19%), Black (40%), Hispanic (30%), Other (11%). No data on proportions with any co-morbidity. 100% on ART, 58% CD4 &gt;200 cells/µL, 81% VL &lt;50 copies/µL.</td>
<td>18 (21%) COVID-19 deaths in PLWH versus 81 (20%) in adults without HIV</td>
<td>JBI C = 6. Follow up not complete for all patients. Matched on limited number of confounders. Potential over-adjustment.</td>
</tr>
<tr>
<td>Vizcarra et al [14], 2020</td>
<td>Case series of 51 PLWH with suspected/confirmed COVID-19</td>
<td>Madrid</td>
<td>84% male mean age 53.3 years, 88% white ethnicity. 100% receiving ART, median CD4 565 cells/µL, 98% virally suppressed, 63% with ≥1 comorbidity.</td>
<td>2 PLWH died (4%) vs 20% amongst general population admitted to nearby hospital with COVID-19.</td>
<td>JBI CS = 7. Comparison group from a different population. COVID-19 case definition unclear. Not all cases completed follow up.</td>
</tr>
<tr>
<td>Study</td>
<td>Setting</td>
<td>Design</td>
<td>Case series</td>
<td>Characteristics</td>
<td>Mortality</td>
</tr>
<tr>
<td>------------</td>
<td>------------------</td>
<td>-------------------</td>
<td>--------------------------------------</td>
<td>------------------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Shalev et al [15], (2020)</td>
<td>Single centre: New York, US</td>
<td>Case series of 31 PLWH hospitalised for COVID-19 at a large tertiary care medical centre in New York City.</td>
<td>77% male, mean age 60.7 years, 52% black, 29% Hispanic, 9% white, 100% receiving ART, median CD4 396 cells/µL, 100% virally suppressed, 71% with ≥ 1 comorbidity</td>
<td>8 PLWH died (27.6%), no mortality comparison given</td>
<td>JBI CS = 8. Not all cases completed follow up.</td>
</tr>
<tr>
<td>Karmen-Tuohy et al [16], (2020)</td>
<td>Multi centre: 4 hospitals in New York, US</td>
<td>Cohort study of 21 PLWH hospitalised with confirmed COVID-19 compared to a matched cohort of 42 HIV-negative patients (selected from 2617 non-HIV patients with COVID-19 at same centres)</td>
<td>90.5% male, mean age 60 years, 24% African American, 38% White, 38% Other, 100% receiving ART, median CD4+ 298 cells/µL, 71% VL &lt;50 copies/mL</td>
<td>6 PLWH died (28.6%) vs 10 (23.8%) in HIV-negative cohort (p=0.682)</td>
<td>JCI C = 11.</td>
</tr>
<tr>
<td>Childs et al [17], (2020)</td>
<td>Single centre: London, UK</td>
<td>Case series of 18 PLWH hospitalised with confirmed COVID-19.</td>
<td>67% male, median age 52, 94% black ethnicity, 100% on ART, median CD4 395 cells/µL, 94% virally suppressed</td>
<td>5 PLWH died (29%), no mortality comparison given</td>
<td>JCI CS = 6. Time period of enrolment and follow up time not defined.</td>
</tr>
</tbody>
</table>

* Joanna Briggs Institute [JBI] Cohort Study [C] or Case Series [CS] checklist items completed, with comment. See Tables S2 and S3 for full scores.

1. Adjusted for age, sex, diabetes, tuberculosis history and other co-morbidities (hypertension, kidney disease, lung disease)
2. Adjusted for age, sex, deprivation, ethnicity, obesity, smoking, and presence of comorbidities (hypertension, chronic respiratory disease, chronic cardiac disease, diabetes, non-haematological cancer, haematological cancer, chronic liver disease, stroke, dementia, other neurological disease, reduced kidney function, organ transplant, asplenia, rheumatoid arthritis, lupus, psoriasis, or other immunosuppressive disorders)
3. Matched on age, gender, ethnicity, smoking, body mass index, diabetes, hypertension and chronic lung diseases
4. Adjusted for age, sex, ethnicity, baseline date, indeterminate/probable hospital acquisition of COVID-19, ten co-morbidities, and disease severity at presentation
5. Matched on age, sex, race/ethnicity and week of SARS-CoV-2 infection
6. Matched on age, gender, body mass index, smoking, co-morbidities (chronic kidney disease, hypertension, asthma, chronic obstructive pulmonary disease, heart failure) and admission date, all from same centre

ART = antiretrovirals, PLWH = people living with HIV, VL = viral load.
Table 2: Summary of studies reporting outcomes by ART regimen and other risk factors for adverse COVID-19 outcomes amongst people living with HIV

<table>
<thead>
<tr>
<th>STUDY</th>
<th>INFLUENCE OF ART REGIMENS</th>
<th>OTHER RISK FACTORS AMONG PLWH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boulle et al, (2020) [18]n=3978</td>
<td>Lower mortality in patients on TDF vs abacavir/zidovudine (aHR: 0.42; 95% CI: 0.22;0.78)</td>
<td>601 patients had CD4 count measured during episode of C-19. Higher mortality associated with CD4 counts &lt;200 cells/µL (n=70) vs ≥350 cells/µL (aHR 1.97; 95% CI 1.14-3.40). Direction of causality unclear. No difference in hazard of C-19 death by HIV VL (aHR vs HIV-negative: 2.61 (95% CI: 1.98-3.43) for VL &lt; 1000 copies/mL; 3.35 (95% CI: 1.38-6.12) for VL ≥ 1000 copies/mL or CD4 &lt;200 cells/µL).</td>
</tr>
<tr>
<td>Bhaskaran et al [27], (2020)</td>
<td>N/A</td>
<td>PLWH of Black ethnicity had higher risk of COVID-19 mortality (aHR 3.80, p for interaction 0.045). No data on outcomes by CD4 or VL.</td>
</tr>
<tr>
<td>del Amo et al, (2020) [11]n=236</td>
<td>Lowest risk for C-19 diagnosis (16.9% [95% CI: 10.5 - 25.9]) &amp; hospitalisation (10.5 [95% CI: 5.6 - 17.9] ) in PLWH receiving TDF/FTC compared to other ART regimens (e.g. ABC/3TC 28.3% [95% CI: 21.5 - 36.7] and 23.4% [95% CI: 17.2 - 31.1] respectively).</td>
<td>Higher crude risk of C-19 death amongst older PLWH (70-79 years = 26.6/10,000, 95% [CI 10.7–54.9] vs 50-59 years 2.2/10,000 [95% CI 10.7-54.9]). No difference by sex.</td>
</tr>
<tr>
<td>Ho et al [20], (2020) n=93</td>
<td>No significant difference in TDF use between PLWH with C-19 who survived and died (73.6% vs 55.5%, p=0.15).</td>
<td>No significant differences in obesity, CD4 counts or HIV VL between PLWH with C-19 who survived and died</td>
</tr>
<tr>
<td>Di Biagio et al [21], 2020 n=69</td>
<td>No stat. sig. association between risk of hospitalisation and ART regimens</td>
<td>Hospitalised PLWH were slightly older (p=0.047). No association between most recent VL or CD4 count and hospitalisation.</td>
</tr>
<tr>
<td>Maggiolo et al [22], (2020) n=55</td>
<td>No difference in TDF use amongst PLWH with C-19 (60%) vs without C-19 (60.8%)</td>
<td>4 PLWH with C-19 who died had lower last CD4 count (median 514 cells/µL) than the 51 PLWH who survived (median 913 cells/µL).</td>
</tr>
<tr>
<td>Etienne et al [23], (2020) n=54</td>
<td>No stat. sig. difference between ART regimen and C-19 severity</td>
<td>No stat. sig. association between CD4 counts or VL &lt; 40 copies/ml and C-19 severity</td>
</tr>
<tr>
<td>Inciarte et al [24], (2020) n=53</td>
<td>No associations between ART regimen and C-19 severity</td>
<td>No association between latest CD4 count and C-19 severity</td>
</tr>
<tr>
<td>Huang et al [26], 2020 n=35</td>
<td>N/A</td>
<td>Older age and ART discontinuation associated with C-19 infection. No association between latest CD4 count or VL and C-19 infection.</td>
</tr>
<tr>
<td>Study</td>
<td>n</td>
<td>N/A</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------</td>
<td>-----</td>
</tr>
<tr>
<td>Geretti et al [28], (2020)</td>
<td>115</td>
<td>N/A</td>
</tr>
<tr>
<td>Sigel et al [13], (2020)</td>
<td>88</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vizcarra et al, [14], (2020)</td>
<td>51</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shalev et al [15], (2020)</td>
<td>31</td>
<td>N/A</td>
</tr>
<tr>
<td>Karmen-Tuohy et al [16], (2020)</td>
<td>21</td>
<td>N/A</td>
</tr>
<tr>
<td>Childs et al [17], (2020)</td>
<td>18</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3TC = lamivudine, ABC = abacavir, FTC = emtricitabine, ART = antiretroviral therapy, BMI = body mass index, C-19 = COVID-19, OR = odds ratio, PLWH = people living with HIV, stat. sig. = statistically significant, TAF = tenofovir alafenamide, TDF = tenofovir disoproxil fumarate, VL = viral load
Figures

Figure 1: PRISMA Flow diagram to show studies identified and included in a systematic meta-analysis of outcomes of COVID-19 in people living with HIV (PLWH)

Figure 2 Meta-analysis of the effect of HIV on risk of COVID-19 death.

Figure 2 caption: Country; UK = United Kingdom, US = United States of America, ZA = South Africa. HIV+ and HIV- refers to people with and without HIV. C19 refers to those with COVID-19. The denominators (N) refer to the original population where reported: A cohort of people diagnosed with HIV and the wider general population without HIV. Not all studies reported this information. Results are reported as hazard ratios (HR) with 95% confidence intervals (95%CI).
Records identified through database searching (n = 1908)

Additional records identified through other sources (n = 6)

Records screened (n = 1914)

Records excluded (n = 1712)

Title and abstract assessed for eligibility (n = 202)

Articles excluded (n = 153): not a case series/observational study (n=110), ≤ 15 participants (n=37), duplication (n=6)

Full-text articles assessed for eligibility (n = 49)

Full-text articles excluded (n = 30): no clinical outcomes (n=13), lack of relevant comparisons (n=17)

Studies included in qualitative synthesis (n = 19)

Studies included in quantitative synthesis (meta-analysis) (n = 5)
<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>N</th>
<th>C19 Death</th>
<th>N</th>
<th>HIV- C19 Death</th>
<th>N</th>
<th>HIV- Death</th>
<th>Hazard Ratio</th>
<th>HR</th>
<th>95%-Cl</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boulle</td>
<td>ZA</td>
<td>540552</td>
<td>3978</td>
<td>115</td>
<td>2920380</td>
<td>18330</td>
<td>510</td>
<td></td>
<td></td>
<td>2.14 (1.70 to 2.70)</td>
<td>47.8%</td>
</tr>
<tr>
<td>Bhaskaran</td>
<td>UK</td>
<td>27480</td>
<td>n/a</td>
<td>25</td>
<td>17255425</td>
<td>n/a</td>
<td>14857</td>
<td></td>
<td></td>
<td>2.30 (1.55 to 3.42)</td>
<td>20.6%</td>
</tr>
<tr>
<td>Hadi</td>
<td>US</td>
<td>n/a</td>
<td>404</td>
<td>20</td>
<td>n/a</td>
<td>404</td>
<td>15</td>
<td></td>
<td></td>
<td>1.33 (0.69 to 2.57)</td>
<td>8.2%</td>
</tr>
<tr>
<td>Geretti</td>
<td>UK</td>
<td>n/a</td>
<td>115</td>
<td>26</td>
<td>n/a</td>
<td>47424</td>
<td>13955</td>
<td></td>
<td></td>
<td>1.63 (1.07 to 2.48)</td>
<td>18.6%</td>
</tr>
<tr>
<td>Karmen-Tuohy</td>
<td>US</td>
<td>n/a</td>
<td>21</td>
<td>6</td>
<td>n/a</td>
<td>42</td>
<td>10</td>
<td></td>
<td></td>
<td>1.20 (0.50 to 2.85)</td>
<td>4.8%</td>
</tr>
</tbody>
</table>

**Random effects model**

Heterogeneity: $\hat{I}^2 = 11\%$, $\hat{t}^2 = 0.0065$, $p = 0.34$